Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or North Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to North Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. North Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Thomas Williamson (NPI 1023429941)

Field	Value
Entity Type	Individual
Organization	Thomas Williamson
Address	1 Medical Center Blvd
City	Winston Salem
State	NC
ZIP	27157
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 13, 2014

Payer Source	Total Paid
Medicare	$2.4M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-focused practice: Total Medicare revenue is $2.4M and there is no Medicaid billing on file, so the provider operates as a single-payer (Medicare) participant in the available data. The absence of Medicaid claims means analyses of state-level Medicaid market share or dual-coverage patient flows are not possible from these files.

Revenue is highly concentrated in a small set of immunotherapy and related injectables — the precomputed top 3 Medicare codes account for 63.7% of the provider's Medicare revenue, led by J9271 at 35.6%, J9299 at 18.7%, and J0897 at 9.5%. This concentration indicates most Medicare dollars flow through a few high-cost drug codes rather than diversified ancillary or procedural lines.

The CPT/HCPCS mix signals an infusion-centered hematology/oncology practice: large volumes of J9271 (pembrolizumab), J9299 (nivolumab), and J0897 (denosumab) alongside chemotherapy administration codes such as 96413 and supportive agents like J2506 and J1568. These codes are consistent with ongoing systemic cancer therapy and in-office infusion operations rather than a primarily consultative or procedural surgical practice.

Competitive standing by code shows a modest-to-strong national presence on key oncology drugs: J9271 ranks #295 of 1841 providers nationally (84th percentile; typical, unremarkable volume for this code), J9299 ranks #196 of 505 providers (61th percentile; typical, unremarkable volume for this code), and J0897 ranks #801 of 10057 providers (92th percentile; typical, unremarkable volume for this code). In other words, the provider is not among the very largest national centers for pembrolizumab or nivolumab but appears comparatively prominent for denosumab relative to the national provider pool.

There are notable statistical outliers in utilization mix that deserve attention: 99214 is labeled an "extreme outlier, far above typical national volume for this code," with 1.1K claims and $91.1K revenue (3.9% of Medicare revenue), suggesting unusually high E/M visit billing for an oncology specialist. Conversely, J9311 shows an anomalous national rank (#5 of 5 providers, 0th percentile) in a very small comparator set; the dataset labels it "typical, unremarkable volume for this code," but the national sample size is minimal and should be interpreted cautiously.

Claim volumes emphasize infusion throughput: the dataset reports 22.4K claims for J9271, 18.2K claims for J9299, and 12.2K claims for J0897, which together drive the majority of drug-related revenue. These claim counts, paired with additional chemotherapy administration entries (e.g., 96413 with 487 claims and G0498 with 65 claims), are consistent with a high-volume infusion workflow rather than a low-visit consult model.

The provider has an established billing tenure: NPI enumerated 2014-05-13 (~12 years ago), indicating roughly a decade of presence in the Medicare billing data. That tenure, combined with $2.4M in Medicare revenue, supports the interpretation of a stable, operational oncology practice rather than a newly entered or transient billing entity.

From a risk/opportunity perspective, the heavy reliance on a small set of high-cost oncology injectables creates revenue sensitivity to shifts in Medicare reimbursement policy, utilization management, or changes in clinical prescribing patterns for J9271, J9299, and J0897. Given there is no Medicaid billing on file, any payer diversification strategy (e.g., engaging Medicaid or additional commercial contracts) would materially change the payer mix and could mitigate concentration risk, but such opportunities are not visible in the current data.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

65 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	22,400	$40	$828.8K
J9299	Injection, nivolumab, 1 mg	18,160	$20	$435.8K
J0897	Injection, denosumab, 1 mg	12,240	$20	$220.3K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	6,030	$30	$205K
J9311	Injection, rituximab 10 mg and hyaluronidase	4,260	$30	$123.5K
J9312	Injection, rituximab, 10 mg	1,630	$60	$104.3K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,080	$80	$91.1K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	850	$80	$68.2K
J1439	Injection, ferric carboxymaltose, 1 mg	54,000	$1	$54K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	490	$80	$39.4K

Showing 1–10 of 65

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 65 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. North Carolina Distribution

Thomas Williamson — 8 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — North Carolina

Full comparison — all codes billed, vs. state median

65 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	3	30	9,600	$40	$528.3K
J9299	2	10	10,800	$20	$295.8K
J9312	15	20	2,070	$60	$178.1K
83521	3	10	100	$20	$152.9K
J1568	1	10	4,120	$30	$138.3K
J9311	1	10	4,260	$30	$124.8K
J0897	16	430	2,100	$20	$63.9K
J2506	2	10	850	$80	$61K
J3490	12	80	50	$450	$24.1K
J1439	4	30	16,500	$1	$23.1K

Showing 1–10 of 65

Related Providers

Other providers that share a Tax Identification Number (TIN) with Thomas Williamson, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Guangzhi Qu	MS	Hematology & Oncology Physician	$9.1M	$0
Tammy Young	MS	Medical Oncology Physician	$5.1M	$0
Justin Baker	MS	Hematology & Oncology Physician	$4.1M	$0
Nicole Cleveland	MS	Medical Oncology Physician	$2.8M	$0
Manubhai Patel	MS	Medical Oncology Physician	$1.9M	$0
Elizabeth Herrington	MS	Medical Oncology Physician	$1.9M	$0
Natale Sheehan	MS	Medical Oncology Physician	$1.4M	$0
Bobby Graham	MS	Hospice and Palliative Medicine (Internal Medicine) Physician	$143.8K	$0
Donald Tisdale	MS	Family Nurse Practitioner	$113.4K	$0
Meaghan Johnson	MS	Family Nurse Practitioner	$98.5K	$0

Nearby Providers

Other providers in the same ZIP code as Thomas Williamson, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Wake Forest University Health Sciences	NC	Multi-Specialty Clinic/Center	$0	$188.2M
North Carolina Baptist Hospital	NC	General Acute Care Hospital	$0	$138.4M
Wake Air Care LLC	NC	Air Ambulance	$2.5M	$2.4M
Vishak John	NC	Ophthalmology Physician	$4.3M	$0
Omar Sangueza	NC	Dermatopathology (Pathology) Physician	$810.1K	$0
Jennifer Stanislaus	NC	Anesthesiology Physician	$557.1K	$0
Thomas Sullivan	NC	Diagnostic Radiology Physician	$18.9K	$393.7K
Rajiv Shah	NC	Ophthalmology Physician	$328.3K	$0
Bradley Unruh	NC	Diagnostic Radiology Physician	$279.6K	$0
Jordan Allem	NC	Cardiovascular Disease Physician	$257.3K	$0

Thomas Williamson — Billing Profile & Reimbursement Data

Sign up for Thomas Williamson — Billing Profile & Reimbursement Data policy alerts

Thomas Williamson — Billing Profile & Reimbursement Data

Sign up for Thomas Williamson — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References